News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|April 4, 2025

Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children

Author(s)Aaron S. Farberg, MD

Aaron Farberg, MD, discuss how appropriate monitoring, including regular assessments of growth, potential side effects, and laboratory tests to evaluate liver function and hematologic parameters, would be necessary when prescribing a topical JAK inhibitor to a younger child (age 2-11 years).

Episodes in this series

1 expert in this video

EP. 1 Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis

1 expert in this video

EP. 2 Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability

1 expert in this video

EP. 3 Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists

1 expert in this video

EP. 4 Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children

1 expert in this video

EP. 5 Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies

1 expert in this video

EP. 6 Safety Considerations in Pediatric Atopic Dermatitis Treatments

1 expert in this video

EP. 7 Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects

1 expert in this video

EP. 8 Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children

1 expert in this video

EP. 9 Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies

1 expert in this video

EP. 10 The Impact of Atopic Dermatitis on Quality of Life and the Role of New Therapies

1 expert in this video

EP. 11 Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis

1 expert in this video

EP. 12 The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients

1 expert in this video

EP. 13 Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11

1 expert in this video

EP. 14 Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes

1 expert in this video

EP. 15 Things to Consider With Treatment Sequencing for Pediatric Atopic Dermatitis

1 expert in this video

EP. 16 Identifying and Addressing Critical Gaps in Pediatric Atopic Dermatitis Treatment with Ruxolitinib Cream

1 expert in this video

EP. 17 Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis

1 expert in this video

EP. 18 Treatment Escalation and De-escalation Strategies in Pediatric AD: Positioning Ruxolitinib Cream in Clinical Decision-Making

1 expert in this video

EP. 19 Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?

1 expert in this video

EP. 20 The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies

1 expert in this video

EP. 21 Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines

1 expert in this video

EP. 22 Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments

1 expert in this video

EP. 23 Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice

1 expert in this video

EP. 24 Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management

EP. 25 Closing the Gap in Pediatric Atopic Dermatitis: Experts Push for Steroid-Free Advancements

EP. 25 Closing the Gap in Pediatric Atopic Dermatitis: Experts Push for Steroid-Free Advancements

This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

Video content above is prompted by the following:

What kind of monitoring, if any, do you believe would be necessary when prescribing a topical JAK inhibitor to a younger child (age 2-11 years)?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Reviewing Type 2 Inflammation Through a Different Lens

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

Dermatology Conferences and Meetings Calendar: December 2025

© 2025 MJH Life Sciences^®

All rights reserved.